We found a novel hypodysfibrinogenemia designated Tsukuba I caused by compound heterozygous nucleotide deletions with FGG c.1129+62_65 del AATA and FGG c.1299+4 del A on different alleles. The former was deep in intron 8 of FGG and the latter in exon 9 of FGG (Ex-9 deletion), which is translated for the '-chain, but not the A-chain. A Western blot analysis of plasma fibrinogen from our patient revealed an aberrant -chain that migrated slightly faster than the normal B-chain. Materials and Methods: To clarify the complex genetic mechanism underlying Tsukuba I's hypodysfibrinogenemia induced by nucleotide deletions in two regions, we generated two minigenes incorporating each deletion region, transfected them into Chinese Hamster Ovary (CHO) cells, and analyzed RT-PCR products. We also established CHO cells producing the recombinant variant fibrinogen, '409A (Ex-9 deletion). Results and Conclusions: Minigene I incorporating the IVS-8 deletion showed two products: a normal splicing product and the unspliced product. Minigene II incorporating the Ex-9 deletion only produced the unspliced product. The established '409A-CHO cells secreted variant fibrinogen more effectively than normal fibrinogen. Therefore, the aberrant splicing products derived from the IVS-8 deletion cause hypofibrinogenemia most likely due to nonsense-mediated mRNA decay and the partial production of normal Aand '-chains; moreover, the Ex-9 deletion causes hypodysfibrinogenemia due to the absence of normal Aand '-chain production 3 (hypofibrinogenemia) and augmented aberrant '-chain production (dysfibrinogenemia).
Introduction
Fibrinogen is a 340-kDa plasma glycoprotein that is composed of two sets of three different polypeptide chains: A, B, and , which are linked by an extensive network of 29 intra-and inter-chain disulfide bonds and represented as (A-B-)2 [1] . Three chains are coded by FGA, FGB, and FGG (located as a cluster on chromosome 4q31), respectively [2] , and synthesized, assembled into a six-chain molecule in hepatocytes, secreted into blood, and circulated at 1.8-3.5 g/l. [3] . The mature polypeptide of the B-chains is composed of 461 residues, whereas two sets of FGA and FGG products exist due to alternative transcription and translation. The major A-chain (98-99% of the A-chain) contains 610 residues (translated from the first five exons of FGA), while the alternative A-chain (1-2% of the A-chain) contains 846 residues and is translated from all six exons of FGA [4] . The predominant form of the -chain, A (85-93% of the -chain) contains 411 residues, and the variant form of the -chain, ' (7-15% of the -chain) consists of 427 residues [5, 6] . The A-chain is produced by the translation of all 10 FGG exons, while the '-chain is produced by alternative splicing and polyadenylation of the -chain mRNA transcript, resulting in the translation of exons 1-9 of FGG [7, 8] . A major fraction (84%) of plasma fibrinogen contains a homodimer referred to as (A-B-A)2orA/A,and the minor fraction contains a heterodimer (15% of plasma fibrinogen) referred to as (A-B-A(A-B-') orA/' and a homodimer (1% of plasma fibrinogen) referred to as (A-B-')2 or '/' [5, 6] .
More than 300 different mutations in the fibrinogen genes, FGA, FGB, and FGG, have been associated with the phenotype of afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, renal amyloidosis, or fibrinogen storage disease, as listed in the fibrinogen variant data base [9] . Hypofibrinogenemia or afibrinogenemia has been defined as reduced or negligible levels of immunologically determined fibrinogen in plasma, and dysfibrinogenemia has been defined as reduced levels of functionally determined fibrinogen with normal levels of immunologically determined fibrinogen in plasma. In the past three decades, genetic abnormalities in patients with these diseases have been detected in all three genes and identified as missense, nonsense, or frameshift mutations, splice-site abnormalities, or large deletions [9] . Hypodysfibrinogenemia, which is rarer and has the characteristics of dysfibrinogenemia and hypofibrinogenemia, has mainly been reported in FGB or FGG, and is caused by a heterozygous missense or one or two residue deletion mutations [9] .
We recently identified a novel compound heterozygous variant (designated as Tsukuba I) with FGG c.1129+62_65 del AATA and FGG c.1299+4 del A, mutations on separate alleles.
The former was deep in intron 8 of FGG, while the latter was in exon 9 of FGG, a region that is translated for the '-chain, but not the A-chain. In order to clarify the complex genetic mechanism responsible for Tsukuba I's hypodysfibrinogenemia, we produced two minigenes incorporating each deletion region, transfected them into Chinese Hamster Ovary (CHO) cells, and analyzed RT-PCR products. We also established CHO cells producing the recombinant 6 variant fibrinogen, '409A (Ex-9 deletion).
Materials and methods
This study was approved (#383) by the Ethical Review Board of Shinshu University School of Medicine. After informed consent had been obtained from the patient, blood samples were collected for biochemical and genetic analyses.
Patient and coagulation tests
The propositus of Tsukuba I was a 23-year-old man who had no history of bleeding or thrombosis. He was admitted to hospital due to the heavy use of alcohol and severe abdominal pain. Although he was a heavy user of alcohol, he was not diagnosed with alcohol abuse.
Coagulation screening tests showed a low plasma fibrinogen level.
The prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen concentrations, which were measured using the Clauss method, were evaluated by the automated analyzer, Coapresta 2000 (Sekisui Medical CO., Tokyo, Japan). Immunological fibrinogen concentrations were measured by a latex photometric immunoassay using anti-fibrinogen antibody-coated latex particles (Mitsubishi Chemical Medicine Co., Tokyo, Japan) [10] . The thrombin clotting time for plasma was measured without Ca ions, as described by Martinez [11] . 7 
DNA sequence analysis
Genomic DNA was extracted from white blood cells using a DNA Extraction WB kit (Wako Pure Chemical Ltd., Osaka, Japan), according to the manufacturer's instructions. In order to analyze all exons and exon-intron boundaries in the A-, B-, and -chain genes, PCR and direct sequencing were performed as described elsewhere [12] . Furthermore, PCR products were subcloned into pCR2.1 plasmid vectors (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions [13] .
Characterization of plasma fibrinogen
The characterization of proteins was performed by sodium dodecyl sulfate Biotech, Buckinghamshire, UK). Blots were exposed on Hyperfilm-ECL (Amersham Pharmacia Biotech, Buckinghamshire, UK) [14] .
Construction of expression vectors for the analysis of fibrinogen -chain gene transcripts
DNA fragments spanning from intron 7 to exon 9 of the-chain gene (minigene I) and
from intron 8 to the 3' untranslated region (UTR) of the -chain gene (minigene II) were amplified using the patient's genomic DNA and primer couples: the sense primer located in FGG-IVS7 (5'-CCTACGAAAGAGGGAACTTC-3') and antisense primer located in FGG-exon 9 (5'-TTCATGGAATACCACCGGGT-3'), or the sense primer located in FGG-IVS8 (5'-CTTCATAGACTTGCAGAGG-3') and antisense primer located in FGG-UTR (5'-GCTTTGCAAGTCCATTGTCC-3'). Purified minigene I (wild type 1;
Wt1:1983 bp, mutant type 1; Mt1:1979 bp) and minigene II (Wt2:819 bp, Mt2:818 bp) were inserted into the pTARGET Vector and transfected into JM109 High Efficiency Competent Cells using the pTARGET TM Mammalian Expression Vector System (Promega, Co., Madison, WI, USA) according to the manufacturer's instructions [12] . Plasmid DNAs were purified using a miniprep method and nucleotide sequences were confirmed. 9 Expression vectors were introduced into CHO cells using lipofectamine reagent (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol. Transfected CHO cells were cultured in 5% CO2 at 37 °C. CHO cells were harvested 48 h after transfection.
Total cellular RNA was extracted from cells using the QIAamp RNA Blood Mini Kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. Reverse-transcriptase (RT) reactions were performed using the oligo dT primer and RT from Moloney murine leukemia virus [13] , followed by PCR amplification with two pairs of primers: the sense primer located in FGG-exon 8 (5'-CATGTTCAAGGTGGGACCTG-3') and antisense primer located in FGG-exon 9 (5'-TTCATGGAATACCACCGGGT-3') for minigene I, or the sense primer located in FGG-exon 9 (5'-GTGGCACTTACTCAAAAGCATC-3') and antisense primer located in FGG-3' UTR (5'-CTCTCTGTTCAGATAAAGTCC-3') for minigene II.
RT-PCR-amplified products were separated by electrophoresis on 2% agarose gels and purified from the gels using the Gene Clean II Kit (Funakoshi, Tokyo, Japan). DNA fragments were sequenced as described above using the primers used for RT-PCR.
Expression of recombinant variant fibrinogen
Recombinant variant fibrinogen was prepared as previously described. Briefly, the variant fibrinogen -chain expression vector, pMLP-'409A was altered from the pMLP-' plasmid (kindly provided by Lord ST, University of North Carolina), which contained wild-type'-chain cDNA, by oligonucleotide-directed mutagenesis using the Quick Change II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) [14] and the following primer pair (the altered base is underlined); sense: 5'-GCCAAACAGGTC_GACCAGAGCACCCTGCG-3' and antisense:
The resultant mutant and normal expression vectors were co-transfected with the histidinol selection plasmid (pMSVhis) into CHO cells that expressed normal human fibrinogen A-and B-chains (AB CHO cells) using a standard calcium-phosphate co-precipitation method [15] . The cell lines were designated as '409Aand normal ('N)-CHO cells, respectively. Cells were cultured and colonies were selected on histidinol (Aldrich Chem. Co. Milwaukee, WI, USA), as described elsewhere. Fibrinogen concentrations in cell lysates or culture media from the selected clones were measured by the enzyme-linked immunosorbent assay (ELISA) [10] , and the assembly of fibrinogen and/or synthesis of three polypeptide chains in the cell lysate was analyzed by SDS-PAGE and a Western blot analysis as described previously [15] .
Statistical analysis
The significance of differences in fibrinogen synthesis and secretion between ' 409A-, and 'N-CHO cells was analyzed using a one-way ANOVA (analysis of variance) and Tukey-Kramer tests. A difference was considered significant when p < 0.05. (wild-type) plus Ex-9 deletion positive. In brief, the mutations were on different alleles (Supplement Figure 1) . Unfortunately, we did not perform the coagulation screening test or DNA sequence analysis on the parents of the patient.
Results

Coagulation screening tests and DNA sequence analysis
Characterization of plasma fibrinogen.
We performed a Western blot analysis on the propositus's plasma fibrinogen. Under non-reducing conditions, an anti-human fibrinogen antibody indicated that Tsukuba I fibrinogen had a higher molecular weight than normal fibrinogen ( Fig. 2A ). On the other hand, under reducing conditions, four bands corresponding to the A-, B-, -, and '-chains for normal fibrinogen, and an additional band that migrated slightly faster than the normal B-chain was detected in Tsukuba I fibrinogen (Fig. 2B ). As shown in Figure 2C with an anti-human fibrinogen -chain antibody, the additional band was clearly and abundantly present in Tsukuba I fibrinogen, indicating that the additional band was the variant -chain.
However, an anti-human fibrinogen '-chain antibody (specific for '408-427) did not react with the variant -chain (Fig. 2D) . The amount of the '-chain of Tsukuba I was smaller than that of the normal -chain.
Analysis of fibrinogen -chain gene transcripts in CHO cells.
In order to verify whether the nucleotide deletions of IVS-8 and Ex-9 influence the 13 transcription of mature mRNAs, mutant -chain mRNAs were transiently produced in CHO cells and analyzed as described in the "Materials and methods" section. The construction of minigene I incorporating the IVS-8 deletion was shown in Figure 3A . The RT-PCR products from CHO cells transfected with wild-type minigene I; Wt1 showed a single band that was named W1, and those from CHO cells transfected with mutant type minigene I; Mt1 showed two bands, which were named M1-1 and M1-2, respectively (Fig. 3A) . Furthermore, the amount of M1-1 was larger than that of M1-2. Direct sequencing demonstrated that W1 and M1-2 were the normal splicing products constituting exons 8 and 9, whereas M1-1 was the unspliced product.
The construction of minigene II incorporating the Ex-9 deletion was shown in Figure 3B .
The RT-PCR products from CHO cells transfected with wild-type minigene II; Wt2 showed a single band that was named W2, and those from CHO cells transfected with mutant type minigene II; Mt2 showed a single band, which was named M2 (Fig. 3B ). Direct sequencing revealed that the mRNA of W2 was the normal splicing product of exons 9 and 10. On the other hand, the mRNA of M2 was the unspliced product.
We showed the Tsukuba I propositus's predicted amino acid sequence from the minigene expression results ( Fig. 4A and 4B) . The IVS-8 deletion (c.1129+62_65 del AATA) partially caused the splicing abnormality and nucleotides in intron 9 were translated, resulting in the connection of 12 aberrant amino acids (351-362), ultimately giving a premature termination 14 codon (Fig. 4A ). On the other hand, the Ex-9 deletion (c.1299+4 del A) resulted in the absence of splicing between exons 9 and 10 for the -chain, and only alternative translation in exon 9 was observed, leading to the production of a '-chain possessing 27 aberrant amino acids ('409-435) (Fig. 4B ).
Synthesis and secretion of recombinant variant fibrinogen in CHO cells.
We established 'Nand '409A-fibrinogen-expressing CHO cells. Fibrinogen concentrations in the culture media and cell lysates of fibrinogen-synthesizing cell lines were measured by ELISA. Fibrinogen concentrations in cell lysates of the '409A-fibrinogen-expressing cell lines (n=9) were 165 ± 66 ng/mL and significantly lower than those in the lysates of 'normal cells: 1176 ± 534 ng/mL (n=8) (Fig. 5A ). Culture media from '409A-fibrinogen-expressing cell lines had slightly lower fibrinogen concentrations than those from normal cells (Fig. 5B) ; however, the fibrinogen concentration ratio of the medium/cell lysate was 5.49 ± 1.22 and significantly higher than normal (1.15 ± 0.52) ( Fig.   5C ).
Among the selected cell lines of variant-and normal '-chain-producing cells, cell lysates
were analyzed by SDS-PAGE and a Western blot analysis under non-reducing and reducing conditions, as described in the "Materials and methods" section. The '409A-fibrinogen-expressing cell line synthesized the variant '-chain, and the variant '-chain was assembled into fibrinogen inside cells ( Fig. 5D and E) . Moreover, the relative molecular weight of the aberrant '-chain from the '409A-fibrinogen-expressing cell line was higher than that of the normal '-chain.
Discussion
We identified two novel nucleotide deletions in FGG: compound heterozygous nucleotide deletions with c.1129+62_65 del AATA in intron 8 (IVS-8 deletion) and c.1299+4 del A in exon 9 (Ex-9 deletion), which were present on different alleles. Furthermore, a Western blot analysis of plasma fibrinogen from our patient revealed three bands of -chains: a normal A-chain, aberrant -chain, and '-chain (in order of the amount of protein). Therefore, we analyzed the sequences of mRNA derived from two minigenes from our patient.
The minigene incorporating the IVS-8 deletion produced two mRNAs; one was an unspliced product, resulting in the aberrant -chain consisting of 362 residues (including 12 substituted residues in the C terminus). However, we did not observe the shortened length of the -chain for the patient's fibrinogen; therefore, this aberrant -chain may not exist in plasma. These results suggest that aberrant -chain mRNA possessing the premature termination codon at 363 is destroyed in hepatocytes, most likely through nonsense-mediated mRNA decay [16, 17] . In addition, the minigene incorporating the IVS-8 deletion partially produced a normal splicing product, but at a lower amount than that of the aberrant product. 16 In brief, the IVS-8 deletion may produce smaller amounts of the normal -chain and '-chain than the normal gene, resulting in hypofibrinogenemia.
Deep intronic mutations were easily detected due to advances in the development of next generation sequencing systems, resulting in an increase in reports on deficiency of coagulation factors V [18] , VIII [19, 20] , and IX [21] , and Protein S [22] . In the fibrinogen gene, only three deep intronic mutations were reported by the Sanger sequencing systems;
FGG c.667-320A>T [23, 24] , FGB c.114+2076A>G [25] , and FGB c.115-600A>G [26] . More than 90 % of these deep intronic mutations were one nucleotide substitutions causing the generation of a pseudo-exon (cryptic exon) in mRNA. Four-nucleotide deletions, such as Fibrinogen Tsukuba I's IVS-8 deletion (c.1129 + 62_65 del AATA), were rare among deep intronic mutations. In our search, we only found two reports of similar mutations to Tsukuba I's IVS-8 deletion: one was CFTR c.870-1113_-1110 del GAAT for cystic fibrosis [27] and the other KRIT1 c.262+132_133 del AA for cerebral cavernous malformations [28] , both resulting in the generation of a pseudo-exon in mRNA. However, our experiment using Tsukuba I's IVS-8 deletion minigene indicated that it did not generate a pseudo-exon, but caused incomplete splicing (partially normal splicing). These results are consistent with the findings of a computer-assisted prediction tool program (http://www.fruitfly.org/seq_tools/splice.html). Namely, when AATA was deleted in IVS-8 of FGG, all the splicing site prediction scores were the same as those of the wild-type, indicating that cryptic splice sites were not generated. Therefore, our patient was a rare case of a deep intronic mutation, and the mechanism for this phenomenon needs to be clarified.
The minigene incorporating the Ex-9 deletion only produced extended exon 9 transcription corresponding to '-chain mRNA, whereas the splicing product combining exons 9 and 10 was absent. The aberrant '-chain had 435 residues (including 27 substituted and/or additional residues in the C terminus) and a larger molecular weight than the normal '-chain (426 residues). As a consequence, we detected a high-molecular-weight aberrant '-chain in the Western blot analysis of fibrinogen from the plasma of our patient. Although the mechanism underlying alternative splicing for '-chain mRNA production [7, 8] and the regulation of plasma '-chain levels have not yet been elucidated in detail, plasma fibrinogen contains approximately 7 to 15% '-chains and exists as three types of molecules: AA (84% of total plasma fibrinogen), A' (15%), and '' (1%) [5, 6] . The normal '-chain is synthesized at markedly smaller amounts than the normal A-chain. Our results suggest that Tsukuba I patient's Ex-9 deletion may have disturbed the normal regulation of A-and'-chain mRNA production, resulting in normal A-chain mRNA being completely absent and the production of aberrant '-chain mRNA being strongly enhanced.
Splice-junction mutations, including splice donor sites and acceptor sites, cause a fibrinogen deficiency with splicing abnormalities, and the mutations at position +1 or +2 of donor sites are common in hypo-and/or afibrinogenemia [9] . On the other hand, the mutation at position 18 +4 or +5 site was rarely reported as FGG c.78+5G>A [29] , FGG c.307+5G>A [30] , and FGG c.307+4A>G [31] . Furthermore, we established '409A-fibrinogen-expressing CHO cells, and ELISA and Western blot analyses of cell lysates and conditioned media indicated that the aberrant '-chain was synthesized and assembled into fibrinogen, and then secreted more efficiently than normal control fibrinogen. These results are also consistent with the presence of the aberrant -chain in the plasma of our Tsukuba I patient, and at an amount that was slightly smaller than that of the normal -chain and markedly larger than that of the normal '-chain. In brief, Tsukuba I patient's Ex-9 deletion may lead to hypofibrinogenemia. (Fig. 4B ). This substitution may have led to Tsukuba I patient's impaired thrombin clotting time and lower fibrinogen concentration by the Clauss method.
In conclusion, genetic analyses revealed that our compound heterozygous patient with c.1129+62_65 del AATA in FGG intron 8 and c.1299+4 del A in FGG exon 9 (Tsukuba I) had hypodysfibrinogenemia. Aberrant splicing products derived from the former mutation caused hypofibrinogenemia, most likely due to nonsense-mediated mRNA decay and the partial production of the normal Aand '-chain. In addition, the latter mutation caused hypofibrinogenemia due to the absence of normal Aand '-chain production and also caused dysfibrinogenemia due to augmented aberrant '-chain production. RT-PCR-amplified products from wild-type minigene II-derived mRNA. Mt2:
Authorship
RT-PCR-amplified products from aberrant minigene II-derived mRNA. W2 was mRNA from wild-type minigene II. M2 was mRNA from aberrant minigene II, which is the unspliced product. 
